TrialBMJ open2024

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.

Thomas D Norton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.